1353 GMT - Sanofi has investors worried about its lack of a pipeline to replace blockbuster sales of its Dupixent drug once the medicine goes off patent, but it has financial muscle to pursue deals, Jefferies analysts say. "The question remains how to deal with the Dupixent loss of exclusivity after 2030, which, at this point, will have to largely be an inorganic answer. That in and of itself may not be exciting, but the stock is priced for no answer," the analysts say. It should only take one sensible deal to address the market's concern, they add. The French drugmaker should have between 20 billion and 30 billion euros to spend on deals, according to Jefferies. Shares rise 1.6%.